We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Prenatal Testing with Cell-Free DNA Demonstrated Clinical Benefit

By LabMedica International staff writers
Posted on 06 Feb 2013
Print article
Noninvasive prenatal testing (NIPT) has clinical benefit over conventional prenatal screening tests, and at a price point of USD 795, NIPT demonstrated cost savings to the healthcare system.

An analytic model was used to compare NIPT for trisomy 21, which causes Down syndrome, against conventional prenatal screening with first trimester combined or integrated screening for the US population. Modeling was based on a 4 million pregnant women cohort in the US. While NIPT is not as comprehensive as a karyotype, it does not carry a risk of pregnancy loss.

This is the first study to evaluate the economic impact of NIPT in a high-risk pregnancy population as recommended by the American Congress of Obstetricians and Gynecologists (ACOG) and the Society for Maternal Fetal Medicine (SMFM). As compared to conventional prenatal screening, NIPT detected 65%–85% more cases of trisomy 21, reduced invasive procedures by over 95%, and in turn, reduced over 99% of unnecessary fetal loss. The study appeared online on January 28, 2013, in the Journal of Maternal Fetal and Neonatal Medicine.

"The clinical advantages of implementing noninvasive prenatal testing into clinical practice are becoming increasingly clear and this model quantifies the benefit," said Dr. Aaron Caughey, senior author of the study and chair of Obstetrics and Gynecology at Oregon Health and Sciences University (Portland, OR, USA). "One of the most striking findings is that NIPT can be cost saving to the US healthcare system at the appropriate price. Few, if any, new technologies can demonstrate both clinical and cost benefit. NIPT represents a healthcare advance to achieve the Triple Aim of improved quality, better access, and lower costs."

Produced by molecular diagnostics company Ariosa Diagnostics, Inc. (San Jose, CA, USA) the Harmony Prenatal Test equips pregnant women and their healthcare providers with reliable information to make decisions regarding their health, without creating unnecessary stress or anxiety.

Related Links:
Oregon Health and Sciences University
Ariosa Diagnostics

New
Gold Member
C-Reactive Protein Reagent
CRP Ultra Wide Range Reagent Kit
Unit-Dose Packaging solution
HLX
New
Bordetella Pertussis ELISA
NovaLisa Bordetella Pertussis IgA
New
Automated Nucleic Acid Extraction Instrument
EX9600

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The discovery of a new blood group has solved a 50- year-old mystery (Photo courtesy of 123RF)

Newly Discovered Blood Group System to Help Identify and Treat Rare Patients

The AnWj blood group antigen, a surface marker discovered in 1972, has remained a mystery regarding its genetic origin—until now. The most common cause of being AnWj-negative is linked to hematological... Read more

Microbiology

view channel
Image: The inbiome molecular culture ID technology has received FDA breakthrough device designation (Photo courtesy of inbiome)

Revolutionary Molecular Culture ID Technology to Transform Bacterial Diagnostics

Bacterial infections pose a major threat to public health, contributing to one in five deaths worldwide. Current diagnostic methods often take several days to provide results, which can delay appropriate... Read more

Pathology

view channel
Image: Confocal- & laminar flow-based detection scheme of intact virus particles, one at a time (Photo courtesy of Paz Drori)

Breakthrough Virus Detection Technology Combines Confocal Fluorescence Microscopy with Microfluidic Laminar Flow

Current virus detection often relies on polymerase chain reaction (PCR), which, while highly accurate, can be slow, labor-intensive, and requires specialized lab equipment. Antigen-based tests provide... Read more

Industry

view channel
Image: The GeneXpert system’s fast PCR Xpert tests can fight AMR and superbugs with fast and accurate PCR in one hour (Photo courtesy of Cepheid)

Cepheid Partners with Fleming Initiative to Fight Antimicrobial Resistance

Antimicrobial resistance (AMR) is responsible for over one million deaths globally each year and poses a growing challenge in treating major infectious diseases like tuberculosis, Escherichia coli (E.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.